|
Post by itellthefuture777 on May 7, 2021 22:10:20 GMT -5
www.sciencedirect.com/science/article/pii/S1530891X20483624Ultra Rapid-Acting Inhaled Insulin Improves Glucose Control in Patients With Type 2 Diabetes Mellitus doi.org/10.1016/j.eprac.2020.10.004Get rights and content Under a Creative Commons licenseopen access Abstract Objective To determine whether the use of an inhaled insulin would improve HbA1c. Methods This study was performed in 20 type 2 diabetes mellitus (T2DM) participants with HbA1c values ≥7.5 (58) to ≤11.5% (102 mmol/mol) on a variety of glucose-lowering regimens. Prandial Technosphere insulin (TI) was rapidly titrated based on a treatment algorithm using postprandial blood glucose to calculate premeal doses. A 2-week baseline period was followed by 12 weeks of active treatment with TI. The primary outcome was change in HbA1c. Secondary outcomes included glucose time in range (time in range: 70-180 mg/dL) obtained by a blinded continuous glucose monitoring during the baseline period and at the end of 12 weeks. Goals were to assess how to rapidly and safely initiate TI intensification, determine dosing requirements, and establish an effective dose range in uncontrolled T2DM. Results Mean HbA1c decreased by −1.6% (−17 mmol/mol) from 9.0% (75 mmol/mol) at baseline to 7.4% (57 mmol/mol) at 12 weeks (P < .0001). Mean time in range increased from 42.2% to 65.7% (P < .0002). Mean prandial doses of TI were 18 or 19 units for all meals. Time below range was 1.1% baseline and 2.6% post treatment (P = .01). Conclusion Treatment with inhaled TI dosed using a simple algorithm improved glycemic control measured by both HbA1c and time in range, with low rates of hypoglycemia. These data add significantly to understanding TI in the management of T2DM patients for whom prandial insulin is a consideration.
|
|
|
Post by MnkdWASmyRtrmntPlan on May 10, 2021 10:08:27 GMT -5
Article Info Publication History Published online: December 14, 2020 Accepted: October 15, 2020 Received: July 12, 2020
This is a great study. Although it only involves 20 participants, the results are just what we want to see. The study was completed and submitted in July, 2020 and published in the May, 2021 issue of Endocrine Practice.
Hopefully, eyes will read it that will make a difference.
|
|
|
Post by dh4mizzou on May 10, 2021 10:43:17 GMT -5
Can someone help me with the HbA1c reduction? The Results state that the reduction was 1.6% from 9.0% to 7.4%. While this is a drop of 1.6% I see the reduction as 17.78% (1.6/9.0). Why is the result stated the way it it?
|
|
|
Post by peppy on May 10, 2021 10:59:33 GMT -5
Can someone help me with the HbA1c reduction? The Results state that the reduction was 1.6% from 9.0% to 7.4%. While this is a drop of 1.6% I see the reduction as 17.78% (1.6/9.0). Why is the result stated the way it it? I never noticed this color key before.
|
|
|
Post by ktim on May 10, 2021 16:49:40 GMT -5
Can someone help me with the HbA1c reduction? The Results state that the reduction was 1.6% from 9.0% to 7.4%. While this is a drop of 1.6% I see the reduction as 17.78% (1.6/9.0). Why is the result stated the way it it? That confusion is why in finance it would be referred to as drop of 160bp (basis points). Those in medicine need to be worried when the world of finance has more precision in their terminology.
|
|
|
Post by shawnonafrezza on May 10, 2021 20:26:10 GMT -5
Can someone help me with the HbA1c reduction? The Results state that the reduction was 1.6% from 9.0% to 7.4%. While this is a drop of 1.6% I see the reduction as 17.78% (1.6/9.0). Why is the result stated the way it it? I never noticed this color key before. 99% sure that is based on GRIT work so take the colors with a grain of salt. Calling 5.2 high is crazy.
|
|